Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial
about
Lymphangiogenesis and Lesion Heterogeneity in Interstitial Lung DiseasesLymphangioleiomyomatosis: differential diagnosis and optimal managementManagement of lymphangioleiomyomatosisClinical features, epidemiology, and therapy of lymphangioleiomyomatosisDiffuse Cystic Lung Disease. Part I.A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM).Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.Women with TSC: Relationship between Clinical, Lung Function and Radiological Features in a Genotyped Population Investigated for Lymphangioleiomyomatosis.Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosisTherapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM)Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis.EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.Bilateral spontaneous chylothorax after severe vomiting in children.Transforming growth factor-β1 downregulates vascular endothelial growth factor-D expression in human lung fibroblasts via the Jun NH2-terminal kinase signaling pathway.The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.Lymphangioleiomyomatosis: New Treatment Perspectives.A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.Lymphatic Changes in Respiratory Diseases: More than Just Remodeling of the Lung?Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing Lgals3.A vascular model of Tsc1 deficiency accelerates renal tumor formation with accompanying hemangiosarcomas.Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells.Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.Emerging Roles for VEGF-D in Human Disease.Cystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function.Human Pluripotent Stem Cell-Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis.Smoking-related lung abnormalities on computed tomography images: comparison with pathological findings.An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases.Chronic sirolimus therapy for lymphangioleiomyomatosis.Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.Emerging biomarkers of lymphangioleiomyomatosis.Effect of beta-agonists on LAM progression and treatment.Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM).TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.Immunohistological features related to functional impairment in lymphangioleiomyomatosis.The vitamin D binding protein axis modifies disease severity in lymphangioleiomyomatosis
P2860
Q26773022-19228554-6685-43AF-9760-DA25EF785327Q27022412-CAE339D6-0E84-436D-A606-1A257AA7122EQ28084725-A7CD45BA-DE75-4DBE-A67A-3F763EAD1138Q28084975-5B9D1808-8D1D-4519-A783-23A996ADB0C5Q33722950-8C8C0B70-91FD-49CF-9CF5-6074EA08F809Q34061748-18B7C1BF-BC1A-4EBC-AA5B-15DBA213160EQ34408059-ACF1DFD8-FBBB-4E7F-8104-775E8030BD7EQ36015287-22E216D6-BD76-4F75-8F5B-1DECC7FBE90DQ36125195-87BDB4EA-988D-44A9-8460-8CB345AFE608Q36382124-825734A0-08E5-4CC7-9F35-7E2181985562Q36462100-C5FE4CBF-6B7A-42F9-BC69-AEE3E1EBAECFQ36806587-C6196F52-66DE-4518-A1D7-3E16E770781FQ37241549-A4DA3E66-2A2B-4683-BEB8-42E12ED125C8Q37397803-6C6129D6-6C25-42F2-BDCC-062CB3944BA3Q37524336-7569447E-BF3A-4E00-9FF7-8E64CDA06CEFQ37649952-56D8923E-537E-4AC6-BBAE-3116B1A9B586Q38372196-C97EF38E-9663-4A7F-ACA0-F9600F297257Q38484497-B37227AE-C7FD-4FB0-8280-0F577731D40EQ38676246-E3C5D24B-88A8-4379-B250-A6301BCF9760Q39263241-48F81BAD-C49A-4B5E-97AB-51FCD2159809Q40984224-D9310792-E4D5-4A59-A8D9-2BE43519403EQ41893057-D6AF2D53-8AD2-4808-AF66-B151362E6B2AQ41913382-52C5971B-4ED4-4F23-879C-01C53DEF4422Q42371463-EEB44BD2-CD03-4395-B2AD-735DEDCE05EEQ42595723-37F7F6CC-FA0E-4ECF-B20F-4FABBD16D8F7Q47233157-E0224101-2D1B-4ABD-9F9E-C28E91551703Q47370738-71ABE01A-EBA9-4E87-9224-724EE046C086Q47662133-E268A03E-2B2A-45F7-8BCE-7FCF75F156CAQ47679256-2A962917-26C7-4D7C-BFCF-0737F4E8049AQ47815265-FEB7D130-8AE8-42D2-AE6D-F3BDCC772CC6Q48008829-7B28996A-A08E-4BEF-9020-CA51312C5B8EQ48355779-ADA8023E-CD01-4422-A9FC-52D2F8886E87Q49679457-DB80E47B-C13F-43D0-BCB9-122400733100Q50020089-00B105D6-50C4-4611-8657-14C741C67360Q50630588-F3C091D0-158E-4522-820B-0DCA3C6ECD37Q51474084-23684339-C9F5-4717-B5BF-D6D3FFC83250Q51698891-93AF7297-194B-401D-8C48-A133E3B370F9Q52316792-5680FFE2-140E-4E98-B3B9-CA4AF83EE207Q54979000-ADEA5896-D48C-4504-8A5E-0BAED3271560Q58701361-4AEDDBF2-AAFC-495C-AE53-6FB4FE51B32A
P2860
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Serum VEGF-D a concentration a ...... acy of Sirolimus (MILES) trial
@ast
Serum VEGF-D a concentration a ...... acy of Sirolimus (MILES) trial
@en
Serum VEGF-D a concentration a ...... omatosis Efficacy of Sirolimus
@nl
type
label
Serum VEGF-D a concentration a ...... acy of Sirolimus (MILES) trial
@ast
Serum VEGF-D a concentration a ...... acy of Sirolimus (MILES) trial
@en
Serum VEGF-D a concentration a ...... omatosis Efficacy of Sirolimus
@nl
prefLabel
Serum VEGF-D a concentration a ...... acy of Sirolimus (MILES) trial
@ast
Serum VEGF-D a concentration a ...... acy of Sirolimus (MILES) trial
@en
Serum VEGF-D a concentration a ...... omatosis Efficacy of Sirolimus
@nl
P2093
P2860
P50
P1476
Serum VEGF-D a concentration a ...... acy of Sirolimus (MILES) trial
@en
P2093
Alan F Barker
Angelo M Taveira-DaSilva
Bruce C Trapnell
Hilary J Goldberg
Hye-Seung Lee
James M Stocks
Jeffrey J Swigris
Jeffrey P Krischer
Jeffrey T Chapman
P2860
P304
P356
10.1016/S2213-2600(13)70090-0
P577
2013-08-01T00:00:00Z